W. Niezychowski

发表

Challenges and Opportunities in IBD Clinical Trial Design.

R. Collins, C. O'Morain, M. Silverberg, 2021, Gastroenterology.

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

S. Vermeire, P. Higgins, B. Sands, 2017, Gut.

The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study

Steven W. Martin, S. Vermeire, J. Dahlerup, 2011, Gut.

767 Efficacy and Safety of Oral Tofacitinib As Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis: Results From Two Phase 3 Randomized Controlled Trials

S. Vermeire, B. Sands, G. D'Haens, 2016 .

OP032 Efficacy and safety of oral tofacitinib as maintenance therapy in patients with moderate to severe ulcerative colitis: results from a phase 3 randomised controlled trial.

S. Vermeire, B. Sands, G. D'Haens, 2017, Journal of Crohn's & colitis.

Phase 2 Randomized Study of CP-690,550, an Oral Janus Kinase Inhibitor, in Active Crohn's Disease

W. Sandborn, J. Panés, Subrata Ghosh, 2011 .

Exposure–response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose‐ranging phase 2 trial

Steven W. Martin, D. Mould, Mike K. Smith, 2018, British journal of clinical pharmacology.

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

W. Sandborn, J. Panés, Subrata Ghosh, 2012, The New England journal of medicine.

A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease.

W. Sandborn, J. Panés, Subrata Ghosh, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

S. Vermeire, B. Sands, G. D'Haens, 2017, The New England journal of medicine.

Tu1109 Evaluation of the Relationship Between Fecal Calprotectin Concentrations and Clinical and Endoscopic Outcome Measures in a Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

W. Sandborn, J. Panés, C. Su, 2013 .

Long‐term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open‐label, 48‐week extension study

P. Higgins, G. D'Haens, G. Chan, 2017, Alimentary pharmacology & therapeutics.

Long‐term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open‐label, 48‐week extension study

P. Higgins, G. D'Haens, G. Chan, 2017, Alimentary Pharmacology and Therapeutics.

Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials

S. Vermeire, B. Sands, W. Sandborn, 2021, Alimentary pharmacology & therapeutics.

Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial.

W. Sandborn, J. Panés, C. Su, 2016, Gastroenterology.

W1042 Mechanistic Population Pharmacokinetics (PK) Model of PF-00547659, a Fully Human IgG2 Anti-MAdCAM Antibody, in Ulcerative Colitis Patients: Results of a First in Human (Fih) Study

Steven W. Martin, G. Burgess, M. Magnusson, 2009 .

861 Safety and Efficacy of Pf-00547,659, a Fully Human Anti-MAdCAM Antibody, in Ulcerative Colitis. Results of a First in Human Study

S. Vermeire, J. Dahlerup, J. Panés, 2009 .

Tofacitinib for Maintenance Therapy in Patients With Active Ulcerative Colitis in the Phase 3 OCTAVE Sustain Trial: Results by Local and Central Endoscopic Assessments: 607

S. Vermeire, B. Sands, W. Sandborn, 2017 .

Tofacitinib Has Induction Efficacy in Moderately to Severely Active Ulcerative Colitis, Regardless of Prior TNF Inhibitor Therapy: 570

T. Hibi, B. Sands, W. Sandborn, 2016 .

855 Efficacy and Safety of Tofacitinib for Oral Induction Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial

S. Vermeire, B. Sands, G. Chan, 2016 .

OP031 Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2 open-label 48-week extension study.

P. Higgins, G. D'Haens, G. Chan, 2017, Journal of Crohn's & colitis.